SPR741 + aztreonam

SPR741 + aztreonam is a combination therapy consisting of **SPR741**, a novel polymyxin B derivative with minimal intrinsic antibacterial activity, and **aztreonam**, a monobactam β-lactam antibiotic. SPR741 acts as a potentiator by permeabilizing the outer membrane of Gram-negative bacteria, thereby enhancing the uptake and efficacy of coadministered antibiotics, such as aztreonam. This combination is designed to target multidrug-resistant (MDR) Gram-negative bacteria, especially those with resistance to conventional antibiotics. SPR741’s modifications result in reduced nephrotoxicity relative to traditional polymyxins. The combination has shown activity against MDR pathogens in vitro and in preclinical models, providing a potential therapeutic strategy for resistant infections where aztreonam alone would be ineffective due to insufficient penetration or resistance mechanisms[1][2].